Xtalks to Host Webinar on AI and Molecular Advances in Hematologic Cancer Drug Development
In a press release, Xtalks announced a free webinar titled "Redefining Hematologic Malignancy Drug Development: How Molecular Reclassification, MRD, & AI is Reshaping Precision Hematology," scheduled for April 30, 2026, at 11 a.m. EDT. The event will explore how molecular reclassification and artificial intelligence are influencing precision medicine in hematologic cancers.
The session will feature Maria Prendes, Head of Scientific Affairs at NeoGenomics, and Maria Ignacia Berraondo, Executive Medical Director at Fortrea. They will discuss the use of molecular residual disease (MRD) as a surrogate endpoint in drug development and the role of AI-driven digital hematopathology in improving diagnostic precision.
The webinar aims to highlight how integrating molecular diagnostics, multi-omic data, and AI-based predictive modeling can accelerate therapeutic assessment and refine patient stratification in hematologic malignancies. Registration for the event is open through the Xtalks website.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice Operations Oct 15 Study Tracks 270 Million Clinical AI Queries on OpenEvidence Oct 15 OpenAI Offers US University Labs Free GPT-Rosalind AccessLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Xtalks Plans Webinar on AI for Antibody Process Optimization
MediSights Reports Study Using AI Agents for Myeloma Market Research
Linearis Joins Two Canadian AI Health Data Projects
ADLM to Brief Congress on Healthcare AI Policy
EMA Plans Webinar on Enterprise AI Governance Gaps
Daily AI Brief: the AI news that matters, in your inbox.